Charles River Laboratories International (CRL) Capital Expenditures (2009 - 2026)

Charles River Laboratories International has reported Capital Expenditures for 18 years, with the latest figure at $31.1 million in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 11.88% year-over-year to $31.1 million in Q2 2026; TTM through Jun 2026 was $211.5 million, a 1.24% increase from a year earlier, with the FY2025 full-year figure at $219.2 million, down 5.93% from the prior year.
• Capital Expenditures was $31.1 million for Q2 2026 at Charles River Laboratories International, down from $55.9 million in the prior quarter.
• The five-year high for Capital Expenditures was $106.9 million in Q2 2023, with the low at $31.1 million in Q2 2026.
• Average Capital Expenditures over 5 years is $65.7 million, with a median of $69.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 187.06% in 2022, then sank 41.4% in 2024.
• Over 5 years, Capital Expenditures stood at $89.0 million in 2022, then decreased by 12.02% to $78.3 million in 2023, then declined by 3.46% to $75.6 million in 2024, then increased by 17.63% to $89.0 million in 2025, then slumped by 65.03% to $31.1 million in 2026.
• The last three Capital Expenditures figures came in at $31.1 million (Q2 2026), $55.9 million (Q1 2026), and $89.0 million (Q4 2025), per Business Quant data.